Close Menu

NEW YORK – Thermo Fisher Scientific and Daiichi Sankyo said today that they have partnered to develop a companion diagnostic for patients with non-small cell lung cancer (NSCLC).

The assay will use Thermo Fisher's Oncomine Dx Target sequencing test. It will be designed to identify NSCLC patients with mutations in HER2 who may be eligible for treatment with Enhertu (DS-8201), a HER2-directed antibody-drug-conjugate under development at Daiichi that is currently being tested in Phase II for HER2-mutated or HER2-overexpressing NSCLC.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.